Advertisement

Topics

CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders

11:05 EDT 12 Jul 2018 | BioMedReports - Blog

  • Announces non-binding Letter of Intent to acquire CCR5-focused cancer company ProstaGene LLC
  • Maintains commitment to advancing PRO 140 clinical programs in HIV and graft-versus-host disease
  • Advancing plans to submit BLA for PRO 140 in combination therapy for HIV

VANCOUVER, Washington, July 12, 2018 (GLOBE NEWSWIRE)

Read more...

Original Article: CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders

NEXT ARTICLE

More From BioPortfolio on "CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...